« Return to News | Clinical Intelligence

FDA issues complete response to Protalix

Tuesday, March 1, 2011 08:33 AM

The FDA has issued a complete response letter for Protalix's Gaucher's disease drug taliglucerase alfa. Protalix won't be required to conduct any additional clinical studies, but that didn't stop its stock from plunging on the news, FierceBiotech reported.

The FDA's main concerns were with clinical and chemistry, manufacturing and controls. The agency wants additional data from Protalix's switchover trial and long-term extension trial. At the time the NDA was submitted, full information from these trials was not available, the company noted in a release. The FDA wants information on testing specifications and assay validation.

"While we are disappointed by the receipt of the Complete Response Letter, we appreciate the FDA's efforts to complete the review of our NDA,” said Protalix CEO David Aviezer. “We noted that the FDA did not request additional clinical studies. Moreover, the FDA inspected our manufacturing facilities, finding them acceptable. FDA also did not identify any issues in its audit of our clinical sites." The company said it will meet with the FDA to determine its next steps.

Gaucher's is a rare genetic disease in which lipids accumulate in the organs, resulting in organ enlargement and bone pain. Pfizer has partnered with Protalix since 2009 on the drug, an oral recombinant protein therapeutic. If approved, taliglucerase alfa could erode market share of Genzyme's Cerezyme, which has faced shortages due to manufacturing problems.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.